Analysts Are Bullish on These Healthcare Stocks: RDUS, ICPT

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Radius Health (NASDAQ: RDUS) and Intercept Pharma (NASDAQ: ICPT) with bullish sentiments.

Radius Health (NASDAQ: RDUS)

Canaccord Genuity analyst John Newman maintained a Buy rating on Radius Health (NASDAQ: RDUS) today and set a price target of $85. The company’s shares opened today at $42.92.

Newman noted:

“Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology.”

According to TipRanks.com, Newman is a 1-star analyst with an average return of -0.7% and a 43.3% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Synergy Pharmaceuticals Inc.

Currently, the analyst consensus on Radius Health is Moderate Buy and the average price target is $52.80, representing a 23.0% upside.

In a report issued on July 17, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $65 price target.
Intercept Pharma (NASDAQ: ICPT)

Cowen & Co. analyst Ritu Baral reiterated a Buy rating on Intercept Pharma (NASDAQ: ICPT) today. The company’s shares opened today at $128.

Baral observed:

“ICPT reported $30.4M 2Q sales of Ocaliva for PBC, easily beating consensus of.”

According to TipRanks.com, Baral is a 5-star analyst with an average return of 16.3% and a 53.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Global Blood Therapeutics, and Intra-Cellular Therapies.

Currently, the analyst consensus on Intercept Pharma is Moderate Buy and the average price target is $174.67, representing a 36.5% upside.

In a report issued on July 17, Oppenheimer also maintained a Buy rating on the stock with a $200 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.